Zinc
Zinc is a trace element; studies show benefits especially for diarrhea and respiratory infections in children, but for colds they contradict each other.
We evaluated 330 human studies on Zinc, including 198 randomised controlled trials and 75 meta-analyses or systematic reviews; the controlled studies include 42,118 participants in total. As of 5 October 2026.
1. What Is Zinc? Occurrence, Origin and Forms
Zinc is a trace element that the body cannot produce itself and can store only to a limited extent. It occurs in animal and plant foods and is taken up through the diet, and is additionally supplied as salts or as compounds bound to organic carriers. Supply is common when intake is insufficient; in studies, zinc is examined in contexts such as the common cold, wound healing and diarrhoea in children.
Zinc occurs in soils, water and many foods, especially meat, seafood, legumes and seeds. In the body it is present in many tissues and enzymes.
Zinc is obtained from zinc ores; for supply it is bound to salts or organic carriers, for example as sulfate, gluconate, citrate, picolinate or acetate. In studies these forms are examined individually, at different amounts and over different periods of time, as is zinc oxide for topical use.
Forms and Preparations Studied
- Zinc sulfate
- Zinc gluconate
- Zinc citrate
- Zinc picolinate
- Zinc acetate
- Zinc oxide for topical use
Not covered on this page:
- Zinc pyrithione in anti-dandruff products, a different compound with cosmetic use
- Zinc oxide as a UV filter in sunscreens, which serves light protection and is not a zinc supply
- Zinc in infusion and dialysis solutions, which are not supplied via the gastrointestinal route
2. What Does Zinc Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Respiratory tract infections | mostly improved | high | 6 meta-analyses · 7 controlled · 7 other | 3,862 |
| Common cold | mostly no difference | high | 6 meta-analyses · 4 controlled · 2 other | 320 |
| Immune function | mixed | high | 2 meta-analyses · 7 controlled · 5 other | 811 |
| Diarrhoea in children | mixed | high | 4 meta-analyses · 5 controlled · 1 other | 10,933 |
| Skin | mostly improved | high | 1 meta-analyses · 4 controlled · 2 other | 220 |
| Taste | mostly no difference | moderate | 1 meta-analyses · 3 controlled · 2 other | 123 |
| Wound healing | mostly no difference | unclear | 0 meta-analyses · 2 controlled · 3 other | 42 |
| Other investigations | mostly improved | high | 41 meta-analyses · 174 controlled · 58 other | 31,397 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Zinc and Respiratory Tract Infections: Human Studies
In adults without known zinc deficiency, zinc somewhat prevented mild respiratory infections in two reviews 1114. Both reviews come from the same working group 1114. In treatment, the symptoms subsided earlier, but the certainty of these data is low 1114. The strongest symptoms were less severe, but the average symptom severity was not 1114. In children under five years, preventive zinc reduced the frequency of pneumonia in one review 12. A larger review found no difference for lower respiratory tract infections in children 4. In a region with zinc deficiency, young children taking zinc gluconate fell ill again less often with lower respiratory tract infections 120. In Laos, preventive or therapeutic zinc did not change the number of respiratory infections in young children 78. US cadets had more symptom-free phases with zinc gluconate, but not fewer medically diagnosed infections 215. In children with pneumonia in hospital, zinc shortened hospital stay in two randomized trials 127168. In a third study, it shortened only cough and runny nose 122. A meta-analysis found fewer deaths from pneumonia in children under five years 3. In adults with COVID-19 in hospital, intensive care need or death occurred less often with zinc acetate 156. This study was small and unblinded 156. Predominantly oral zinc forms such as zinc sulfate, zinc gluconate and zinc acetate were investigated, sometimes also sublingual or intranasal, in varying amounts and durations. Combination products do not allow any statement about zinc alone. Echinacea with zinc and vitamin C shortened upper respiratory infections compared with placebo 90. A tablet with aspirin, promethazine, vitamins, zinc and selenium alleviated symptoms in COVID-19 93. A product with pelargonium extract, honey, propolis and zinc alleviated sore throats in children more than standard treatment 245. An early review also suspects a benefit for SARS-CoV-2; study results for this were still pending 71. The studies in children mostly come from countries with widespread zinc deficiency. They cannot be readily transferred to well-nourished people.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Rouhani et al. 2022 | meta-analysis · 237,068 participants | Zinc supplementation (form not stated); ≥10 mg/day in subgroup analysis; Intervention <11 months, follow-up <1 year; vs. Placebo/control in RCTs | Mortality from pneumonia: improved (0.70: 0.64, 0.98) |
| 4 Imdad et al. 2023 | systematic review · 219,584 participants | Preventive zinc supplementation, mostly zinc sulfate syrup; mostly 10 mg to 15 mg daily; median follow-up 26 weeks; vs. no intervention, placebo, or waiting list | Mortality due to LRTI: improved (RR 0.86, 95% CI 0.64 to 1.15); Morbidity due to LRTI: no difference (RR 1.01, 95% CI 0.95 to 1.08) |
| 11 Hunter et al. 2021 | systematic review · 5,446 participants | Zinc formulations oral, intranasal or sublingual; not reported; not reported; vs. Placebo or active control | RTIs prevented per 100 person-months: improved (5 RTIs per 100 person-months (95% CI 1 to 8, NNT=20)); Symptom duration (days earlier): improved (2 days earlier (95% CI 0.61 to 3.50)); Proportion still symptomatic on day 7: improved (19 more adults per 100 (95% CI 2 to 38, NNT=5)) |
| 12 Lassi et al. 2016 | systematic review · 5,193 participants | Zinc supplementation (form not stated); vs. Placebo or control | Incidence of pneumonia: improved (RR 0.87; 95% CI 0.81 to 0.94); Prevalence of pneumonia: improved (RR 0.59; 95% CI 0.35 to 0.99); Incidence of pneumonia by specific clinical criteria: improved (RR 0.79; 95% CI 0.0.71 to 0.88) |
| 14 Hunter et al. 2020 | systematic review · 3,597 participants | Zinc (oral, sublingual, topical nasal); oral 15-45 mg/day; sublingual 45-300 mg/day; nasal 0.09-2.6 mg/day; not reported; vs. Placebo or active control | Prevention of respiratory tract infections: improved (5 mild to moderate RTIs per 100 person-months); Treatment: peak symptom severity: improved (mean difference 1.2 points, 0.7 to 1.7); Treatment: average daily symptom severity: no difference (standardised mean difference 0.2, 0.1 to 0.4) |
| 48 De et al. 2026 | systematic review · 51 participants | Zinc supplementation, therapeutic or prophylactic; heterogeneous dosing, not standardized; variable treatment duration; vs. placebo or control, per study | resolution of respiratory infections: improved (improved the resolution of respiratory infections) |
| 50 Banerjee et al. 2026 | systematic review | zinc (form not specified), part of a micronutrient review; vs. low vs. normal zinc levels; supplementation vs. none | higher infection rates with low zinc: worsened |
| 71 Arentz et al. 2020 | systematic review | Zinc in various forms, alone or as adjunct; vs. Placebo or active control | risk, duration and severity of SARS-CoV-2 infections: unclear |
Further studies in this area: 78 120 122 127 156 168 215 283 299 303 315 317
Zinc and Common Cold: Human Studies
Preventively, zinc hardly changed the risk of colds in a large systematic review 9. Also in healthy adults, the number of colds remained the same 72. With an existing cold, the duration was shorter with zinc 972. The certainty of these data is low. Meta-analyses of lozenges with zinc acetate or zinc gluconate found a significantly shorter duration than with placebo 354445. Two of them evaluate the same patients 4445. A study with commercially available zinc acetate lozenges, however, found no difference 133. After discontinuation, the zinc group there even recovered more slowly 133. Zinc nasal spray with zinc lozenges did not shorten colds in a placebo-controlled study 268. Some participants had pain in the olfactory area 268. Mixed preparations do not allow conclusions about zinc alone. Zinc with high-dose vitamin C alleviated runny nose 123. An herbal formula with vitamin C and zinc shortened the symptoms 170. It is open which composition of lozenges works best 3544.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 9 Nault et al. 2024 | systematic review · 8,526 participants | Zinc in various forms, mostly lozenges (gluconate, acetate, orotate); Zinc gluconate 45 to 276 mg/day; 4.5 to 21 days (treatment); follow-up 5 to 18 months (prevention); vs. Placebo | Risk of developing a cold: no difference (RR 0.93, 95% CI 0.85 to 1.01); Mean number of colds over 5 to 18 months: no difference (MD -0.90, 95% CI -1.93 to 0.12); Duration of colds in days: no difference (MD -0.63, 95) |
| 11 Hunter et al. 2021 | systematic review · 5,446 participants | Zinc formulations oral, intranasal or sublingual; not reported; not reported; vs. Placebo or active control | Clinical colds following human rhinovirus inoculations: no difference (RR 0.96, 95% CI 0.77 to 1.21) |
| 35 Hemilä et al. 2017 | meta-analysis · 575 participants | Zinc lozenges of zinc acetate or zinc gluconate; >75 mg/day; 80-92 mg/day or 192-207 mg/day; vs. Placebo | Duration of the common cold: improved (33% (95% CI 21% to 45%) shorter); Duration of the common cold (zinc acetate): improved (shortened by 40%); Duration of the common cold (zinc gluconate): improved (shortened by 28%) |
| 44 Hemilä et al. 2017 | meta-analysis · 199 participants | zinc acetate lozenges; 80-92 mg/day elemental zinc; from symptom onset, assessed to day 5; vs. placebo lozenges | recovery rate (rate ratio): improved (3.1 (95% confidence interval, 2.1-4.7)); proportion recovered on day 5: improved (70% of the zinc patients had recovered compared with 27% of the placebo patients); number needed to treat on day 5: improved (2.3) |
| 45 Hemilä et al. 2016 | meta-analysis · 199 participants | Zinc acetate lozenges; vs. Placebo | Duration of common cold: improved (2.73 days (95% CI 1.8, 3.3 days) shorter); Duration of common cold: improved (2.94 days (95% CI 2.1, 3.8 days) reduction) |
| 72 Wang et al. 2020 | systematic review | Oral zinc supplementation (form not stated); vs. Placebo/control or other micronutrients | Cold duration: improved (reduce cold duration by 2.25 days (when zinc is provided singly, 95% CI: -3.39, -1.12)); Cold incidence: no difference; Symptom severity: no difference |
| 123 Maggini et al. 2012 | randomised controlled · 94 participants | 1000 mg vitamin C plus 10 mg zinc; 1000 mg vitamin C + 10 mg zinc; 5 days of treatment; vs. Placebo | rhinorrhoea duration: no difference (nonsignificant reduction of rhinorrhoea duration (range 9-27%)); rhinorrhoea over 5 days: improved (significantly more efficient than placebo); symptom relief: improved (symptom relief was quicker) |
| 133 Hemilä et al. 2020 | randomised controlled · 87 participants | Zinc acetate lozenges (commercially available); 13 mg elemental zinc, six times per day; maximum 5 days; vs. Placebo lozenges with sucrose octa-acetate | Recovery rate over 10 days: no difference (rate ratio for zinc vs placebo=0.68, 95% CI 0.42 to 1.08; p=0.10); Recovery rate in the 2 days after end of use: worsened (p=0.003) |
Further studies in this area: 154 170 268 320
Zinc and Immune Function: Human Studies
Two meta-analyses of randomized trials found lower levels of the inflammatory marker C-reactive protein with zinc 5861. One concerned diabetes and prediabetes 58, the other also found lower interleukin-6 and tumor necrosis factor-alpha 61. In older nursing home residents with low serum zinc, serum zinc and the number of T cells increased with a higher zinc dose 222. The comparison was with a low zinc dose 222. In HIV patients with zinc deficiency, the activation marker soluble CD14 decreased with zinc gluconate, but other inflammatory markers did not 121. Two studies found no difference in CD4 cell count in HIV patients with zinc gluconate 94173. In COVID-19 patients, antibody levels were lower with zinc acetate than without zinc 156. In young children in Bangladesh, neither zinc tablets nor zinc-containing micronutrient powder changed gene expression or cytokines 119. A mixed preparation of yeast glucans with selenium and zinc caused antibodies to rise more after COVID-19 vaccination than placebo 155. What share zinc has in this is open. The findings mostly come from small studies in special groups and concern laboratory values. Whether this leads to fewer infections remains to be clarified.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 58 Nazari et al. 2024 | meta-analysis | Zinc supplementation (form not specified); vs. Control group (placebo/no supplementation) | C-reactive protein: improved |
| 61 Nazari et al. 2023 | meta-analysis | Zinc supplementation (form not specified); vs. Control group (placebo or no supplementation) | C-reactive protein: improved; Interleukin-6: improved; Tumor necrosis factor-alpha: improved |
| 69 Li et al. 2021 | meta-analysis | Vitamin and mineral supplements, including zinc; vs. Placebo | hs-CRP: improved (MD = - 1.29; 95% CI: - 1.82, - 0.76; P < 0.00001) |
| 94 Freiberg et al. 2020 | randomised controlled · 254 participants | Pharmacy-grade zinc gluconate vs. placebo; 15 mg/day men, 12 mg/day women; 18 months; vs. Placebo, double-blind randomized | CD4 cell count: no difference (AMD, 41.8 cells/mm3; 95% CI, -20.3 to 103.8 cells/mm3; P = .19) |
| 97 Kewcharoenwong et al. 2022 | randomised controlled · 200 participants | Therapeutic dispersible zinc tablets (TZ), daily multiple micronutrient powder (MNP), daily preventive zinc tablets (PZ), placebo powder; 7, 10 or 20 mg/day elemental zinc; vs. Placebo powder (control) | Plasma anti-E. coli IgG levels: improved (significantly increased compared with baseline); Anti-E. coli IgG avidity: improved (increased anti-E. coli IgG avidity in the control and PZ groups) |
| 119 Hayman et al. 2021 | randomised controlled · 100 participants | Zinc MNP (10 mg zinc) or dispersible zinc tablet (10 mg); 10 mg zinc daily; 24 weeks; vs. Placebo powder | Differential peripheral blood gene expression: no difference; Cytokine concentrations: no difference |
| 121 Baissary et al. 2025 | randomised controlled · 95 participants | Zinc gluconate tablets (90 mg elemental zinc) or placebo; 90 mg elemental zinc daily; 24 weeks; vs. Placebo, double-blind, randomized 2:1 | soluble CD14 (monocyte activation marker): improved (-56.31 ng/mL (-263.24; 134.19) vs 101.71 ng/mL (-90.50; 243.20); p = 0.021) |
| 156 Gómez-Zorrilla et al. 2025 | randomised controlled · 71 participants | Oral zinc acetate plus standard of care; 90 mg/day; 14 days; vs. Standard of care alone | Antibody levels at days 14 and 28: worsened |
Further studies in this area: 173 222 289 301 315 318
Zinc and Diarrhoea in Children: Human Studies
In children with acute diarrhea, zinc shortened the duration in a meta-analysis 60. More children recovered than with placebo, also in persistent diarrhea 60. Another review reaches the same conclusion 48. Preventive zinc reduced the frequency and severity of diarrhea in young children, mostly with low zinc levels 107. A large review of preventive administration also found somewhat fewer diarrheas 4. For mortality from diarrhea, no confirmed difference was shown 34. In Laos, zinc had no overall effect on diarrhea in young children 78. Only in children over one and a half years did therapeutic zinc shorten the episodes 78. In addition to probiotics, zinc sulfate syrup shortened recovery time, but not illness severity 249. Most studies investigated zinc sulfate syrup in very different doses 4. It remains open which form and dose are most favorable for which age. A meta-analysis recommends lower doses because they caused vomiting less often 60.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Rouhani et al. 2022 | meta-analysis · 237,068 participants | Zinc supplementation (form not stated); ≥10 mg/day in subgroup analysis; Intervention <11 months, follow-up <1 year; vs. Placebo/control in RCTs | Mortality from diarrhea: no difference (0.85; 0.70, 1.03) |
| 4 Imdad et al. 2023 | systematic review · 219,584 participants | Preventive zinc supplementation, mostly zinc sulfate syrup; mostly 10 mg to 15 mg daily; median follow-up 26 weeks; vs. no intervention, placebo, or waiting list | Mortality due to all-cause diarrhea: no difference (RR 0.95, 95% CI 0.69 to 1.31); Incidence of all-cause diarrhea: improved (RR 0.91, 95% CI 0.90 to 0.93) |
| 48 De et al. 2026 | systematic review · 51 participants | Zinc supplementation, therapeutic or prophylactic; heterogeneous dosing, not standardized; variable treatment duration; vs. placebo or control, per study | duration and severity of diarrheal episodes: improved (consistently reduced the duration and severity of diarrheal episodes) |
| 60 Ali et al. 2024 | systematic review | Zinc supplementation (form not stated); low dose vs high dose compared; vs. Placebo or no zinc | Proportion recovered in acute diarrhoea: improved (RR = 1.07; 95% CI = 1.03, 1.1); Duration of diarrhoea in acute diarrhoea: improved (MD = -13.27 hours; 95% CI = -17.66, -8.89); Proportion recovered in persistent diarrhoea: improved (RR = 1.75; 95% CI = 1.34, 2.30) |
| 76 Edwards et al. 2025 | randomised controlled · 4,500 participants | Zinc supplementation (salt form not stated); 5 mg, 10 mg or 20 mg daily; vs. lower vs. higher zinc dose | any vomiting: no difference (1203 (26.7%)); vomiting with dehydration: worsened (RR: 1.45, 95% CI: 1.10-1.92); vomiting with underweight: worsened (RR: 1.22, 95% CI: 1.05-1.41) |
| 78 Barffour et al. 2020 | randomised controlled · 3,407 participants | Therapeutic zinc, preventive zinc tablets, multiple micronutrient powder; TZ: 20 mg/d for 10 days; PZ: 7 mg/d; MNP: 10 mg zinc/d; 9 months; vs. Placebo | Diarrhea incidence: no difference (0.61 ± 0.01 episodes/100 days at risk); Diarrhea duration: no difference (2.12 ± 0.03 days/episode); Diarrhea incidence in children >18 months (TZ vs. MNP): improved (reduced by 24% (P = 0.035)) |
| 81 Islam et al. 2022 | randomised controlled · 2,886 participants | Zinc in micronutrient powder or dispersible tablets; 4.1 mg or 10 mg zinc daily or alternating days; 24 weeks; vs. Placebo powder | Incidence of diarrhea: no difference; Prevalence of diarrhea: no difference |
| 107 Abd et al. 2022 | randomised controlled · 140 participants | zinc supplement (form not stated); daily, amount not stated; 4 months; vs. placebo | cumulative incidence of diarrhea: improved (P < .05); number of diarrhea episodes per child: improved (P < .05); frequency of stools per day: improved (P < .05) |
Further studies in this area: 249 316
Zinc and Skin: Human Studies
In hemodialysis patients, zinc gluconate alleviated itching in a randomized placebo-controlled trial, but not dry skin 132. A systematic review sees only limited evidence that ingested zinc heals skin warts 75. This is most likely the case with zinc deficiency 75. In children with Hirschsprung disease, the skin was less often sore after surgery with zinc 188. With the cancer drug regorafenib, hand-foot skin reactions occurred less often with zinc 258. Combination products also do not allow any statement about zinc alone here. These include combinations with glutathione and vitamin C 137, with alpha-lipoic acid and biotin 219, as well as an acne care product with pomegranate extract 231. The skin studies are small and short and use different zinc forms.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 75 Simonart et al. 2012 | systematic review | Zinc (systemic); vs. Placebo or other systemic therapies | Total clearance of warts: improved (limited evidence) |
| 132 Tavassoli et al. 2024 | randomised controlled · 87 participants | Zinc gluconate; 210 mg zinc gluconate (30 mg elemental zinc) per day; 12 weeks; vs. Placebo | Pruritus: improved (-0/52 (-0/82 to - 0/22)); Xerosis: no difference |
| 137 Sitohang et al. 2021 | randomised controlled · 83 participants | Oral glutathione supplement with zinc aspartate; 12 weeks; vs. Placebo capsules | Spot ultraviolet reduction in subgroups: no difference (not statistically significant); Spot polarization reduction: no difference (not statistically significant); Skin tone improvement: no difference (not statistically significant) |
| 188 Ibrahim et al. 2025 | randomised controlled · 50 participants | Zinc (form not specified); preoperative; vs. Control group without zinc | Skin excoriation: improved (8% vs. 32%) |
| 258 Huang et al. 2023 | randomised controlled | Zinc supplementation; first 8 weeks of treatment; vs. randomized control group | Incidence of grade ≥2 hand-foot skin reaction: improved |
| 288 Towersey et al. 2023 | study · 51 participants | cleansing gel with salicylic acid 2%, zinc gluconate 0.2%, lipohydroxy acid 0.05%; daily use, amount not reported; 84 days; vs. no control group, open-label | total lesion count: improved (-56.3%); non-inflammatory lesions: improved (-64.0%); inflammatory lesions: improved (-48.2%) |
| 302 Lalosevic et al. 2023 | case-control study | Serum zinc measurement, no zinc supplementation; vs. Alopecia areata group vs. healthy controls | Serum zinc concentration: worsened (p = 0.017); Prevalence of zinc deficiency: worsened (p = 0.011); Correlation between serum zinc and disease severity: worsened (ρ = 0.006) |
Zinc and Taste: Human Studies
In unexplained taste disorders, zinc gluconate improved taste in a randomized placebo-controlled study 200. A controlled study with zinc picolinate showed a better result in a taste test with filter paper disk method in zinc deficiency taste disorders 269. However, subjective complaints and the whole-mouth test did not improve more than with placebo 269. A second double-blind study with zinc picolinate showed the same pattern 277. A meta-analysis with various zinc salts found improvement in taste disorders more often than with control 26. The individual studies are small and use different zinc forms. It is open which form and dose help for which cause.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 26 Mozaffar et al. 2023 | meta-analysis · 938 participants | Zinc (sulfate, gluconate, picolinate, polaprezinc, acetate); 17–86.7 mg elemental zinc daily; three to six months; vs. Control group | Improvement in taste disorder: improved (RR = 1.38; 95% CI: 1.16, 1.64, p=0.0002); Improvement in taste perception in chronic renal disease (zinc acetate): improved (RR = 26.69, 95% CI = 5.52-129.06, p < 0.0001) |
| 200 Heckmann et al. 2005 | randomised controlled · 50 participants | Zinc gluconate or placebo (lactose); 140 mg/day; vs. Placebo (lactose) | Gustatory function: improved (p <0.001); Severity of dysgeusia: improved (p <0.05) |
| 269 Sakai et al. 2002 | controlled · 73 participants | zinc picolinate, oral capsule; 29 mg zinc picolinate three times daily; 3 months; vs. placebo, double-blind | improvement in subjective symptoms: no difference; whole-mouth taste sensation: no difference; taste assessment by filter paper disk method: improved (significantly better improvement) |
| 277 Sakai et al. 1995 | controlled | Zinc picolinate; vs. Placebo | Improvement by filter-paper disk method: improved; Total subjective recovery: no difference; Improvement by whole mouth method: no difference |
| 312 Nin et al. 2024 | review | Oral zinc therapy: polaprezinc (off-label) and zinc acetate hydrate; vs. Various treatments in patients under and over 65 years | Efficacy of zinc therapy for taste disorders: unclear (low-level evidence); Efficacy of various treatments in older vs. younger patients: no difference (no significant difference) |
| 316 Santos et al. 2022 | review | Zinc supplements (form not specified); ∼50-150 mg/day elemental zinc in adults; vs. no comparison, review | zinc supplementation in taste disorders: improved |
Zinc and Wound Healing: Human Studies
The controlled studies on wound healing tested zinc only in combinations. A skin care product with prebiotics, panthenol and zinc shortened healing time after cryotherapy 149. In pressure ulcers, polaprezinc, a zinc-carnosine complex, worked better than no treatment 271. L-carnosine alone, however, worked just as well 271. A liquid nutritional supplement with arginine, vitamin C and zinc did not significantly reduce pressure ulcers 240. From these mixtures, no independent effect of zinc can be derived. A review on supply during operations links low zinc levels with slower wound healing and more infections 50. Whether targeted zinc administration changes this is still open 50. The studies are small and short.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 36 De et al. 2026 | systematic review · 544 participants | Zinc L-carnosine in mouthwashes, lozenges, mucoadhesive suspensions; vs. Control groups without ZnC | Improved surgical wound healing: improved |
| 50 Banerjee et al. 2026 | systematic review | zinc (form not specified), part of a micronutrient review; vs. low vs. normal zinc levels; supplementation vs. none | delayed healing with low zinc: worsened |
| 240 Sánchez-Sánchez et al. 2026 | randomised controlled | hypercaloric hyperproteic ONS with fiber, omega-3, L-arginine, nucleotides, vitamin C and zinc; 15 and 30 days; vs. hypercaloric hyperproteic ONS with fiber without enrichment | frequency of pressure-related injuries: no difference (did not reach statistical significance); high risk proportion: no difference (72.5% vs 40.9%); PUSH scale: no difference |
| 271 Sakae et al. 2013 | controlled · 42 participants | Polaprezinc (zinc-L-carnosine complex) orally; 150 mg/d polaprezinc (34 mg zinc, 116 mg L-carnosine); maximum 4 weeks; vs. untreated control and L-carnosine group (116 mg/d) | mean weekly improvement in PUSH score: no difference (1.8 ± 0.2, P = .009) |
| 298 Bechara et al. 2026 | cohort study | Serum zinc (no zinc supplementation reported); 12 months follow-up; vs. zinc deficiency vs. adequate zinc levels | wound healing or time to healing: no difference |
Zinc: Further Outcomes in Studies
Further studies tested zinc for very different questions, from metabolic values to pregnancy and infections. Meta-analyses in diabetes and prediabetes found more favorable blood sugar or blood lipid levels with zinc 1721242558. One of them saw a slight increase in LDL cholesterol 25. A broader meta-analysis found no difference in LDL cholesterol, blood pressure and liver enzymes 61. These are laboratory values; whether this leads to fewer cardiovascular diseases remains to be clarified. In menstrual pain, zinc alleviated pain more than placebo in a meta-analysis 28. Mixed preparations concerned, for example, pregnancy 2 or vitamin A in tuberculosis 20; the share of zinc remains open there.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 An et al. 2022 | meta-analysis · 883,627 participants | Zinc supplementation (form not specified); vs. Control group without zinc | Cardiovascular risk factors: improved (moderate- to high-quality evidence for reducing CVD risk factors) |
| 2 Keats et al. 2021 | systematic review · 451,723 participants | Zinc as single nutrient and multiple micronutrient supplements; vs. Folic acid, iron-folic acid, multiple micronutrients, lipid-based nutrients | Maternal anaemia (IFA vs. folic acid): improved (average risk ratio (RR) 0.52, 95% CI 0.41 to 0.66); Low birthweight (IFA vs. folic acid): improved (average RR 0.88, 95% CI 0.78 to 0.99); Low birthweight (MMN vs. iron with/without folic acid): improved (average RR 0.85, 95% CI 0.77 to 0.93) |
| 3 Rouhani et al. 2022 | meta-analysis · 237,068 participants | Zinc supplementation (form not stated); ≥10 mg/day in subgroup analysis; Intervention <11 months, follow-up <1 year; vs. Placebo/control in RCTs | All-cause mortality: improved (SRR: 0.84, 95% CI: 0.74, 0.96); All-cause mortality with follow-up <1 year: improved (0.46; 0.33, 0.63); All-cause mortality at dose ≥10 mg/day: improved (0.56; 0.42, 0.75) |
| 4 Imdad et al. 2023 | systematic review · 219,584 participants | Preventive zinc supplementation, mostly zinc sulfate syrup; mostly 10 mg to 15 mg daily; median follow-up 26 weeks; vs. no intervention, placebo, or waiting list | All-cause mortality: no difference (RR 0.93, 95% CI 0.84 to 1.03); Mortality due to malaria: improved (RR 0.90, 95% CI 0.77 to 1.06); Height: improved (SMD 0.12, 95% CI 0.09 to 0.14) |
| 5 Shahrokhi et al. 2024 | meta-analysis · 163,909 participants | Zinc levels in serum, hair, nail, prostatic fluid/tissue; zinc intake; vs. Prostate cancer patients vs. healthy controls | Serum zinc level: worsened (SMD: -1.11; 95% CI: -1.67, -0.56); Hair zinc level: worsened (SMD: -1.31; 95% CI: -2.19, -0.44); Prostatic fluid or tissue zinc level: worsened (SMD: -3.70; 95% CI: -4.90, -2.49) |
| 6 Carducci et al. 2021 | systematic review · 18,000 participants | Zinc supplementation (form not reported); vs. No zinc supplementation or placebo | Preterm births: no difference (RR 0.87, 95% CI 0.74 to 1.03); Stillbirth: no difference (RR 1.22, 95% CI 0.80 to 1.88); Perinatal deaths: no difference (RR 1.10, 95% CI 0.81 to 1.51) |
| 7 Sajedi et al. 2020 | systematic review · 11,559 participants | Zinc supplementation alone or with iron co-supplementation; Follow-up up to 9 years; vs. Placebo or control (not specified) | Mental development (Bayley Scales II, 6 and 12 months): no difference; Motor development (Bayley Scales II, 6 and 12 months): no difference; Long-term development in preschool and school-age children: no difference |
| 8 Shi et al. 2026 | meta-analysis · 10,262 participants | Magnesium-zinc-calcium-vitamin D supplement; vs. Standard control | Cesarean section rate: no difference (RR = 0.44, 95% CI: 0.15, 1.29) |
Further studies in this area: 10 11 13 14 15 16 17 18 19 20 21 22 23 24 25 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 46 47 48 49 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 73 74 77 79 80 81 82 83 84 85 86 87 88 89 91 92 94 95 96 98 99 100 101 102 103 104 105 106 108 109 110 111 112 113 114 115 116 117 118 121 122 124 125 126 128 129 130 131 132 134 135 136 138 139 140 141 142 143 144 145 146 147 148 150 151 152 153 157 158 159 160 161 162 163 164 165 166 167 169 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 216 217 218 220 221 223 224 225 226 227 228 229 230 232 233 234 235 236 237 238 239 241 242 243 244 246 247 248 250 251 252 253 254 255 256 257 259 260 261 262 263 264 265 266 267 269 270 272 273 274 275 276 277 278 279 280 281 282 284 285 286 287 289 290 291 292 293 294 295 296 297 299 300 301 304 305 306 307 308 309 310 311 313 314 316 318 319
4. How Is Zinc Dosed? Preparation, Dose and Duration in Studies
The studies predominantly used oral zinc forms such as zinc sulfate, zinc gluconate, zinc citrate, zinc picolinate and zinc acetate, sometimes also sublingual, intranasal or as lozenges. Individual investigations tested zinc oxide for external use as well as zinc-L-carnosine in mouth rinses and adhesive suspensions. Form, amount and duration of intake varied considerably between the studies, which limits comparability.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Zinc supplementation (salt form not stated) | 5 mg, 10 mg or 20 mg daily | — | 76 |
| Oral AREDS2 nutrient supplements with lower versus higher zinc dosage | — | Median 5 years | 77 |
| Therapeutic zinc, preventive zinc tablets, multiple micronutrient powder | TZ: 20 mg/d for 10 days; PZ: 7 mg/d; MNP: 10 mg zinc/d | 9 months | 78 |
| Daily preventive zinc tablets, multiple micronutrient powders, therapeutic zinc supplements, or placebo | 7 mg/day, 10 mg/day (MNP), 20 mg/day for 10 days (TZ) | ~36 weeks follow-up | 79 |
| Daily zinc tablets, micronutrient powder with zinc, therapeutic zinc supplementation | 7 mg/d zinc; 10 mg/d zinc in powder; 20 mg/d zinc for 10 days per diarrhea episode | approximately 9 months | 80 |
| Zinc in micronutrient powder or dispersible tablets | 4.1 mg or 10 mg zinc daily or alternating days | 24 weeks | 81 |
| Daily zinc (25 mg) and vitamin A (2500 IU) vs. placebo | 25 mg zinc daily | From first trimester to delivery | 82 |
| Quintuply-fortified salt with zinc, iron, vitamin B12, folic acid, iodine | — | 12 months | 83 |
| Quintuply-fortified salt with zinc, iron, vitamin B12, folic acid, iodine | Salt disappearance 6.0 g/adult female equivalent/day, zinc dose not reported | 12 months | 84 |
| Chispuditos®, micronutrient-fortified atole drink (9 mg zinc, 12.5 mg iron) | 9 mg zinc per day (part of mixture) | 18 months | 85 |
| Oral nutrition supplement with multi-minerals and vitamins (contains zinc) | — | 12 weeks | 86 |
| Quintuply-fortified salt (zinc, B-12, folate, iodine, iron) | — | 12 months | 87 |
| Daily zinc tablets (7 mg) or zinc-containing multiple micronutrient powder (10 mg zinc + 13 other micronutrients) or placebo | 7 mg zinc daily (PZ) or 10 mg zinc daily (MNP) | 9 months (36 weeks) | 88 |
| Oral zinc gluconate supplementation | 15 mg/d or 30 mg/d | 6 months | 89 |
| EZC Pak: echinacea-zinc-vitamin C combination, with or without vitamin D | — | 5 days | 90 |
5. Is Zinc Safe? Side Effects in Studies
In the treatment of respiratory infections, mild side effects occurred more often with zinc than with placebo 91114. Nausea and irritation in the mouth and nose are mentioned 1114. With zinc acetate lozenges, more participants reported side effects than with placebo 133. A zinc nasal spray caused pain in the olfactory area in some participants 268. The authors warn against putting zinc into the nose because of reported loss of smell 268. Serious adverse events were not observed in several evaluations 1044. In children, vomiting occurred more often with zinc than without zinc 460. Lower doses caused vomiting less often 6076. In menstrual pain, side effects did not differ in a confirmed way from placebo 28.
| Study | Reported side effects |
|---|---|
| 4 Imdad et al. 2023 | more participants with at least one vomiting episode (RR 1.29) |
| 7 Sajedi et al. 2020 | no adverse effects reported |
| 9 Nault et al. 2024 | Unpleasant taste, loss of smell, vomiting, stomach cramps, diarrhoea (reported) |
| 10 Gulani et al. 2014 | no serious adverse events; a small minority of children vomited shortly after ingestion |
| 11 Hunter et al. 2021 | Non-serious adverse events (nausea, irritation) more frequent |
| 13 Zhou et al. 2024 | Safety assessed via SUCRA ranking |
| 14 Hunter et al. 2020 | no serious AEs; non-serious AEs such as nausea, mouth or nasal irritation |
| 15 Ghadirzadeh et al. 2025 | No diarrhea, rash, or vomiting; publication bias found |
| 16 Yadav et al. 2025 | No differences in adverse events |
| 18 Abdollahi et al. 2020 | not reported |
| 23 Wang et al. 2026 | Zinc supplementation reported as safe |
| 28 Hsu et al. 2024 | no significant difference vs placebo (OR 2.54; 95% CI 0.78-8.26; p = 0.122) |
6. What Remains Open: Limits of the Evidence
- Most data come from countries with widespread zinc deficiency and predominantly concern children, so transferability to adults without zinc deficiency remains open.
- Form, dose and duration of zinc intake are inconsistent between the studies, which makes direct comparison difficult.
- Many individual studies are small and short, and the results often differ greatly between studies.
- Combination products with other substances do not allow any statement about the effect of zinc alone.
- Preventive administration and treatment of an existing illness sometimes led to different results, for example with colds 9.
7. Bottom Line: What Is Established About Zinc
Zinc is a trace element that the body cannot produce itself and can store only to a limited extent. The clearest benefits are shown by controlled trials and meta-analyses for diarrhea and respiratory infections in children, mostly in regions with widespread zinc deficiency. For colds, the reviews contradict each other; for taste disorders and skin diseases, there are individual smaller studies with favorable results. The results depend strongly on zinc form, dose, duration and the population studied. Combination products with other substances do not allow any statement about the effect of zinc alone. Tolerability is predominantly described as good, although mild gastrointestinal side effects such as nausea and vomiting occurred more frequently with zinc.
Frequently Asked Questions
How well has Zinc been studied in humans?
We evaluated 330 human studies on Zinc, including 198 randomised controlled trials and 75 meta-analyses or systematic reviews; the controlled studies include 42,118 participants in total. As of 5 October 2026.
Does Zinc help with respiratory tract infections? What the studies show
Does Zinc help with common cold? What the studies show
Does Zinc help with immune function? What the studies show
Does Zinc help with diarrhoea in children? What the studies show
Does Zinc help with skin? What the studies show
Does Zinc help with taste? What the studies show
What is zinc and what is it studied for?
Zinc is a trace element that the body cannot produce itself and can store only to a limited extent. It is taken in through food and additionally supplied in the form of salts or compounds bound to organic carriers. In studies, zinc is investigated among other things for respiratory infections, skin diseases, diarrhea in children and colds.
Which zinc forms were used in the studies?
The studies predominantly used zinc sulfate, zinc gluconate, zinc citrate, zinc picolinate and zinc acetate, sometimes orally, sublingually or intranasally. Individual investigations tested zinc oxide for external use as well as zinc-L-carnosine in mouth rinses and adhesive suspensions. Form, amount and duration of intake influence absorption and varied considerably between the studies.
Does zinc show an effect for colds?
The reviews contradict each other: Preventively, zinc hardly changed the risk of colds 9, but with an existing cold the duration was shorter 972. The certainty of these data is low. A meta-analysis on zinc acetate lozenges reported faster recovery 44. A randomized controlled trial, by contrast, found no difference and even slower recovery after the end of intake 133. The results vary depending on zinc form, administration and study quality.
What side effects do the studies report?
In the treatment of respiratory infections, mild side effects occurred more often with zinc than with placebo 91114. Nausea and irritation in the mouth and nose are mentioned 1114. With zinc acetate lozenges, more participants reported side effects than with placebo 133. A zinc nasal spray caused pain in the olfactory area in some participants 268. The authors warn against putting zinc into the nose because of reported loss of smell 268. Serious adverse events were not observed in several evaluations 1044. In children, vomiting occurred more often with zinc than without zinc 460. Lower doses caused vomiting less often 6076. In menstrual pain, side effects did not differ in a confirmed way from placebo 28.
What can be derived from combination products with zinc?
Combination products with other substances such as iron, vitamin C, vitamin D or selenium do not allow any statement about the effect of zinc alone. A randomized controlled trial on a combination product of echinacea, zinc and vitamin C found a shorter duration of illness 90. A large review found that iron given at the same time weakened the benefit of zinc in children 4.
Sources
- 1An P, Wan S, Luo Y, Luo J, Zhang X, Zhou S et al. · 2022
- 2Keats EC, Oh C, Chau T, Khalifa DS, Imdad A, Bhutta ZA · 2021
- 3Rouhani P, Rezaei Kelishadi M, Saneei P · 2022
- 4Imdad A, Rogner J, Sherwani RN, Sidhu J, Regan A, Haykal MR et al. · 2023
- 5Shahrokhi Nejad S, Golzari Z, Zangiabadian M, Salehi Amniyeh Khozani AA, Ebrahimi R, Nejadghaderi SA et al. · 2024
- 6Carducci B, Keats EC, Bhutta ZA · 2021
- 7Sajedi F, Shahshahani S, Ghiasvand H, Mosallanezhad Z, Fatollahierad S · 2020
- 8Shi J, Chen K, Tang Y, Ren X, Zhang Y · 2026
- 9Nault D, Machingo TA, Shipper AG, Antiporta DA, Hamel C, Nourouzpour S et al. · 2024
- 10Gulani A, Sachdev HS · 2014
- 11Hunter J, Arentz S, Goldenberg J, Yang G, Beardsley J, Myers SP et al. · 2021
- 12Lassi ZS, Moin A, Bhutta ZA · 2016
- 13
- 14Hunter J, Arentz S, Goldenberg J, Yang G, Beardsley J, Myers SP et al. · 2020
- 15Ghadirzadeh B, Afshar M, Afraie M, Moradveisi B, Moradi Y · 2025
- 16Yadav A, Sivagnanaganesan S, Meena J, Shamim MA, Yadav J, Kumar J · 2025
- 17Ghaedi K, Ghasempour D, Jowshan M, Zheng M, Ghobadi S, Jafari A · 2024
- 18Abdollahi S, Toupchian O, Jayedi A, Meyre D, Tam V, Soltani S · 2020
- 19Mohammadi H, Talebi S, Ghavami A, Rafiei M, Sharifi S, Faghihimani Z et al. · 2021
- 20Wagnew F, Alene KA, Eshetie S, Wingfield T, Kelly M, Gray D · 2022
- 21Khajeh M, Hassanizadeh S, Pourteymour Fard Tabrizi F, Hassanizadeh R, Vajdi M, Askari G · 2024
- 22Atef Abdelsattar Ibrahim H, Bendary M, Sabt A, Saad K · 2025
- 23Wang J, Hu J, Luo Y, Nie J, Deng M, Wang Z · 2026
- 24Heidari Seyedmahalleh M, Montazer M, Ebrahimpour-Koujan S, Azadbakht L · 2023
- 25Loaiza-Giraldo JP, Amigo-Fierro F, Cancino-Castro CI, Donoso-Emig M, Satea M, Farías-Quinteros I et al. · 2026
- 26Mozaffar B, Ardavani A, Muzafar H, Idris I · 2023
- 27Liu X, Zhang W, Chen Y, Rastogi S, Choudhury R · 2023
- 28Hsu TJ, Hsieh RH, Huang CH, Chen CS, Lin WY, Huang YC et al. · 2024
- 29Beran A, Mhanna M, Srour O, Ayesh H, Stewart JM, Hjouj M et al. · 2022
- 30Chitiki GDR, Pandita H, Mehta PK, Deshwali A, Ranjan A, Sood H et al. · 2026
- 31Agare GI, Chidike Ezeorba TP, Michael DC, Agbamu E, Aghoja OC, Alalor CA · 2025
- 32Yang HY, Hung KC, Chuang MH, Chang R, Chen RY, Wang FW et al. · 2023
- 33Mbanefo NR, Uwaezuoke SN, Eneh CI, Odimegwu CL, Chikani UN, Muoneke UV et al. · 2023
- 34Ye J, Cen S, Qi Q, Wang C, Wang J, Wang J et al. · 2026
- 35
- 36De Francesco P, Vescovi P, Pedrazzi G, Giovannacci I · 2026
- 37Talebi S, Miraghajani M, Ghavami A, Mohammadi H · 2022
- 38Mahmoud A, Abuelazm M, Ahmed AAS, Abdalshafy H, Abdelazeem B, Brašić JR · 2022
- 39Kumar M, Swarnim S, Khanam S · 2021
- 40Gong Y, Yang Z, Sun G, Xue X, Zhang X · 2026
- 41
- 42Bansal S, Dutta S, Shah RB, Gupta SK, Singhal S · 2025
- 43Shen YC, Chang YH, Fang CJ, Lin YS · 2019
- 44Hemilä H, Fitzgerald JT, Petrus EJ, Prasad A · 2017
- 45Hemilä H, Petrus EJ, Fitzgerald JT, Prasad A · 2016
- 46Vesterlund GK, Jensen TS, Ellekjaer KL, Møller MH, Thomsen T, Perner A · 2023
- 47Abe SK, Balogun OO, Ota E, Takahashi K, Mori R · 2016
- 48De Rose DU, Mirotta N, Dotta A, Salvatori G, Ronchetti MP, Campogiani L et al. · 2026
- 49Tan NLX, Young M, Lambert K, Dawson J · 2026
- 50Banerjee D, Yadav R · 2026
- 51Bwambale J, Nakawuka B, Mboowa G, Bongomin F, Kwizera R · 2026
- 52Kour S, Chaudhary V, Prakash J, Mandrelle K, Sharma KK, Kumari S et al. · 2026
- 53
- 54Diao S, Feng Y, Peng X, Liu D, Huang L, Zeng L et al. · 2025
- 55
- 56
- 57Ceballos-Rasgado M, Brazier AKM, Gupta S, Moran VH, Pierella E, Fekete K et al. · 2025
- 58Nazari M, Nikbaf-Shandiz M, Pashayee-Khamene F, Bagheri R, Goudarzi K, Hosseinnia NV et al. · 2024
- 59Jazinaki MS, Gheflati A, Moghadam MRSF, Hadi S, Razavidarmian M, Nezhad MY et al. · 2024
- 60Ali AA, Naqvi SK, Hasnain Z, Zubairi MBA, Sharif A, Salam RA et al. · 2024
- 61Nazari M, Ashtary-Larky D, Nikbaf-Shandiz M, Goudarzi K, Bagheri R, Dolatshahi S et al. · 2023
- 62Zavros A, Giannaki CD, Aphamis G, Roupa Z, Andreou E · 2023
- 63Chen Z, Hong Z, Wang S, Qiu J, Wang Q, Zeng Y et al. · 2023
- 64Mallat F, Kaikati J, Kechichian E · 2023
- 65Balboni E, Zagnoli F, Filippini T, Fairweather-Tait SJ, Vinceti M · 2022
- 66
- 67Borges L, Gennari-Felipe M, Dias BB, Hatanaka E · 2021
- 68Tabatabaie M, Soltani S, Mozaffari-Khosravi H, Salehi-Abargouei A · 2021
- 69Li D, Cai Z, Pan Z, Yang Y, Zhang J · 2021
- 70Sridharan K, Sivaramakrishnan G · 2021
- 71Arentz S, Hunter J, Yang G, Goldenberg J, Beardsley J, Myers SP et al. · 2020
- 72
- 73Furihata K, Tsuchikawa M, Miwa T, Naito Y, Oba K, Sakagami M · 2020
- 74Buhling K, Schumacher A, Eulenburg CZ, Laakmann E · 2019
- 75Simonart T, de Maertelaer V · 2012
- 76Edwards JG, Dhingra P, Liu E, Dhingra U, Dutta A, Sudfeld CR et al. · 2025
- 77van Asten F, Chiu CY, Agrón E, Clemons TE, Ratnapriya R, Swaroop A et al. · 2019
- 78Barffour MA, Hinnouho GM, Wessells KR, Kounnavong S, Ratsavong K, Sitthideth D et al. · 2020
- 79Wessells KR, Hinnouho GM, Barffour MA, Arnold CD, Kounnavong S, Kewcharoenwong C et al. · 2020
- 80Barffour MA, Hinnouho GM, Kounnavong S, Wessells KR, Ratsavong K, Bounheuang B et al. · 2019
- 81Islam MM, Black RE, Krebs NF, Westcott J, Long J, Islam KM et al. · 2022
- 82Noor RA, Abioye AI, Darling AM, Hertzmark E, Aboud S, Premji Z et al. · 2020
- 83Thompson L, Goh YE, Jamwal M, Singh BL, Brar GK, Arnold CD et al. · 2025
- 84Goh YE, Duggal M, Das R, Manger MS, Jamwal M, Singh BL et al. · 2025
- 85Alfonso Mayén V, Ogunlusi A, Wright CM, Garcia AL · 2022
- 86Nguyen LT, Nam KD, Duong PT, Pham TCT, Komatsu Y · 2024
- 87Long JM, Goh YE, Duggal M, Das R, Manger MS, Jamwal M et al. · 2026
- 88Barffour MA, Bernstein RM, Hinnouho GM, Wessells KR, Arnold CD, Kounnavong S et al. · 2023
- 89Stewart-Knox BJ, Rae G, Simpson EE, McConville C, O'Connor J, Polito A et al. · 2011
- 90Radhakrishnan A, Spencer S, Yanamala N, Malepati S · 2023
- 91Motadi SA, Mbhenyane XG, Zuma MK, Freeland Graves JH · 2024
- 92Prasad M, Srinivasan S, Jadhav A, Chinnaswamy G, Barr RD, Ladas EJ · 2026
- 93Kumar GS, Vadgaonkar A, Purunaik S, Shelatkar R, Vaidya VG, Ganu G et al. · 2022
- 94Freiberg MS, Cheng DM, Gnatienko N, Blokhina E, Coleman SM, Doyle MF et al. · 2020
- 95Namazzi R, Opoka R, Conroy AL, Datta D, Tagoola A, Bond C et al. · 2023
- 96Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A et al. · 2021
- 97Kewcharoenwong C, Sein MM, Nithichanon A, Khongmee A, Wessells KR, Hinnouho GM et al. · 2022
- 98Partap U, Sharma KK, Marathe Y, Wang M, Shaikh S, D'Costa P et al. · 2023
- 99Long JM, Khandaker AM, Sthity RA, Westcott JE, Matveev A, Black RE et al. · 2022
- 100Bozhedomov VA, Lipatova NA, Bozhedomova GE, Rokhlikov IM, Shcherbakova EV, Komarina RA · 2017
- 101Mahjoub L, Youssef R, Yaakoubi H, Salah HB, Jaballah R, Mejri M et al. · 2024
- 102Reino-Gelardo S, Palop-Cervera M, Aparisi-Valero N, Espinosa-San Miguel I, Lozano-Rodríguez N, Llop-Furquet G et al. · 2023
- 103van der Burg KP, Cribb L, Firth J, Karmacoska D, Mischoulon D, Byrne GJ et al. · 2020
- 104Afzali A, Goli S, Moravveji A, Bagheri H, Mirhosseini S, Ebrahimi H · 2021
- 105Aslam M, Bashir S, Zeb A · 2023
- 106Kadim M, Hegar B, Bardosono S, Timan IS, Gunardi H, Prasetyo D et al. · 2020
- 107Abd El-Ghaffar YS, Shouman AE, Hakim SA, El Gendy YGA, Wahdan MMM · 2022
- 108Yosaee S, Soltani S, Esteghamati A, Motevalian SA, Tehrani-Doost M, Clark CCT et al. · 2020
- 109Libonati GA, Leone A, Martellucci S, Gallo A, Albera R, Lucisano S et al. · 2022
- 110Thompson L, Goh YE, Jamwal M, Singh BL, Brar GK, Arnold CD et al. · 2025
- 111Mughal H, Tufail T, Ain HBU, Rasheed A, Alum EU · 2026
- 112Mazaheri Nia L, Iravani M, Abedi P, Cheraghian B · 2021
- 113Huey SL, Cole NL, Pagani I, González A, Finkelstein JL, Haas JD et al. · 2026
- 114Mandlecha TH, Mundada SM, Gire PK, Reddy N, Khaire P, Joshi T et al. · 2023
- 115Derosa G, D'Angelo A, Romano D, Maffioli P · 2016
- 116Nikkhah M, Vafa M, Abiri B, Golgiri F, Sarbakhsh P, Alaei-Shahmiri F · 2024
- 117Obiagwu HI, Eleje GU, Obiechina NJA, Nwosu BO, Udigwe GO, Ikechebelu JI et al. · 2023
- 118Namazzi R, Mellencamp KA, Bagala I, Conroy AL, Kato C, Birungi I et al. · 2026
- 119Hayman T, Hickey P, Amann-Zalcenstein D, Bennett C, Ataide R, Sthity RA et al. · 2021
- 120Shah UH, Abu-Shaheen AK, Malik MA, Alam S, Riaz M, Al-Tannir MA · 2013
- 121Baissary J, Koberssy Z, Wu Q, Sattar A, Atieh O, Daher J et al. · 2025
- 122Padmini SK, Mahesh K, Durgappa H, Sathiyamoorthi S · 2025
- 123Maggini S, Beveridge S, Suter M · 2012
- 124[Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]Salinas-Casado J, Méndez-Rubio S, Esteban-Fuertes M, Gómez-Rodríguez A, Vírseda-Chamorro M, Luján-Galán M et al. · 2018
- 125Ibrahim N, El Said H, Choukair A · 2022
- 126Rompis JL, Kurniawan R, Manoppo JIC · 2025
- 127Atta A, Aftab A, Shafqat A, Yousuf MH, Ahmed A, Pirzada H et al. · 2024
- 128Seely D, Legacy M, Conte E, Keates C, Psihogios A, Ramsay T et al. · 2023
- 129El-Desouky SS, Omer SMM, Ghouraba RF, Latif RMAA, Kabbash IA, Hadwa SM · 2023
- 130
- 131Kitagawa J, Kobayashi R, Nagata Y, Kasahara S, Ono T, Sawada M et al. · 2021
- 132Tavassoli M, Shahidi S, Askari G, Tavakoli N, Clark CCT, Rouhani MH · 2024
- 133Hemilä H, Haukka J, Alho M, Vahtera J, Kivimäki M · 2020
- 134Rabbani E, Golgiri F, Janani L, Moradi N, Fallah S, Abiri B et al. · 2021
- 135Reddy N, Mundada S, Rathod P, Joshi T, Bhansali P · 2026
- 136Azhdari M, Karandish M, Mozaffari-khosravi H, Cheraghian B, Mohammadi SM · 2026
- 137Evaluating Oral Glutathione Plus Ascorbic Acid, Alpha-lipoic Acid, and Zinc Aspartate as a Skin-lightening Agent: An Indonesian Multicenter, Randomized, Controlled TrialSitohang IBS, Anwar AI, Jusuf NK, Arimuko A, Norawati L, Veronica S · 2021
- 138Kopets R, Kuibida I, Chernyavska I, Cherepanyn V, Mazo R, Fedevych V et al. · 2020
- 139Hosseini B, Jenkins D, Daley P, McBrien K, Murthy S, Condon A et al. · 2026
- 140Buccato DG, Ullah H, De Lellis LF, Morone MV, Larsen DS, Di Minno A et al. · 2024
- 141Chhina GS, Chhabra A, Luthra SR, Khattar S, Singh P, Luthra S · 2024
- 142Ayatollahi H, Rajabi E, Yekta Z, Jalali Z · 2022
- 143Sayadi M, Nowbandegani SJ, Inalou FB, Nazemzadegan B, Javidi Alsaadi S, Eskandari M et al. · 2025
- 144Makiabadi E, Nakhaeizadeh R, Soleimani M, Nasrollahzadeh J · 2024
- 145[Yiqi Zhujing granule for idiopathic oligoasthenozoospermia: a clinical study]Huang XF, He Y, Fan Q, Wang Q, Ning KQ · 2013
- 146Seirafian S, Feizi A, Shahidi S, Badri SS, Rouhani MH, Najafabadi PP et al. · 2023
- 147Sena-Evangelista KC, Pedrosa LF, Paiva MS, Dias PC, Ferreira DQ, Cozzolino SM et al. · 2015
- 148GamalEl Din SF, A M E, Elkhiat Y, Hussein T, AbdElSalam MA, Alam A et al. · 2025
- 149Ariasi C, Romanò C, Tomasi C, Soglia S, Licata G, Rubelli L et al. · 2025
- 150Nani A, Bertuzzi F, Meneghini E, Mion E, Pintaudi B · 2023
- 151Kumagai E, Furumachi K, Kurihara A, Hosokawa K, Hosohata K, Takai S et al. · 2023
- 152The effect of Breezy candy on halitosis: a double-blind, controlled, and randomized studyBarak S, Katz J · 2012
- 153Zlotkin SH, Schauer C, Owusu Agyei S, Wolfson J, Tondeur MC, Asante KP et al. · 2006
- 154
- 155Rodriguez JAM, Bifano M, Roca Goma E, Plasencia CM, Torralba AO, Font MS et al. · 2021
- 156Gómez-Zorrilla S, Sendra E, Du J, Espona M, Fierro-Villegas A, Siverio A et al. · 2025
- 157Rohmawati L, Keumala Sari D, Sitepu M, Rusmil K · 2021
- 158Nazem MR, Asadi M, Adelipour M, Jabbari N, Allameh A · 2023
- 159Lagzi N, Bateni A, Goli R, Talebiazar N · 2023
- 160
- 161Ahmadi M, Khansary S, Parsapour H, Alizamir A, Pirdehghan A · 2023
- 162Janyajirawong R, Vilaichone RK, Sethasine S · 2021
- 163
- 164Mahmoodianfard S, Vafa M, Golgiri F, Khoshniat M, Gohari M, Solati Z et al. · 2015
- 165Liu YL, Zhang MN, Tong GY, Sun SY, Zhu YH, Cao Y et al. · 2017
- 166Yang CH, Ko MT, Peng JP, Hwang CF · 2011
- 167A Randomized, Placebo-controlled Clinical Study Evaluating a Dietary Supplement for Hair GrowthMartin-Biggers J, Barbosa Bueno de Campos ME · 2024
- 168Rerksuppaphol S, Rerksuppaphol L · 2019
- 169Gouzi F, Maury J, Héraud N, Molinari N, Bertet H, Ayoub B et al. · 2019
- 170
- 171Piccirillo M, Mennini M, Felici E, Mauro A, Bernardo L, Baldassarre ME et al. · 2026
- 172Ostadmohammadi V, Namazi MJ, Rezasoltani M, Kheirkhah D, Rajabi M, Sharif A et al. · 2024
- 173Osuna-Padilla IA, Rodríguez-Moguel NC, Aguilar-Vargas A, Tolentino-Dolores M, Perichart-Perera O, Ahumada-Topete V et al. · 2024
- 174Ghaseminejad A, Ghaderi A, Ghotloo S, Akbari H, Bahmani F, Aghadavood E et al. · 2023
- 175Mazaheri M, Aghdam AM, Heidari M, Zarrin R · 2021
- 176
- 177Asghari S, Hosseinzadeh-Attar MJ, Alipoor E, Sehat M, Mohajeri-Tehrani MR · 2019
- 178Payahoo L, Ostadrahimi A, Mobasseri M, Khaje Bishak Y, Farrin N, Asghari Jafarabadi M et al. · 2013
- 179Mousa N, Abdel-Razik A, Zaher A, Hamed M, Shiha G, Effat N et al. · 2016
- 180Karamali M, Heidarzadeh Z, Seifati SM, Samimi M, Tabassi Z, Hajijafari M et al. · 2015
- 181Antoniotti V, Partenope C, Solito A, Mancioppi V, Baima J, Medina F et al. · 2025
- 182Ostadmohammadi V, Samimi M, Mobini M, Zarezade Mehrizi M, Aghadavod E, Chamani M et al. · 2019
- 183Passerieux E, Hayot M, Jaussent A, Carnac G, Gouzi F, Pillard F et al. · 2015
- 184Mesdaghinia E, Naderi F, Bahmani F, Chamani M, Ghaderi A, Asemi Z · 2021
- 185Dirajlal-Fargo S, Yu J, Kulkarni M, Sattar A, Funderburg N, Barkoukis H et al. · 2019
- 186Vázquez-Lorente H, Molina-López J, Herrera-Quintana L, Gamarra-Morales Y, Quintero-Osso B, López-González B et al. · 2022
- 187Vázquez-Lorente H, Herrera-Quintana L, Molina-López J, Gamarra Y, Planells E · 2022
- 188Ibrahim HAA, Kaddah S, Mohamed RME, Khedr S · 2025
- 189El-Haggar SM, Attalla DS, Elhelbawy M, El-Afify DR · 2025
- 190Mousa A, Elgarhi I, Ibrahim B, Atalla E, Abdel-Rasheed M, Nagy O et al. · 2025
- 191Mohammadi F, Mohsenpour MA, Rezaei SMA, Eftekhari MH · 2025
- 192Liu E, Manji KP, Kirby MA, Kisenge R, Lauer JM, Fawzi WW et al. · 2024
- 193The Efficacy of Cryotherapy and Zinc Gluconate in Management of Anogenital Warts: A Randomized Double-Blind, Split-Side, Placebo-Controlled TrialGhahartars M, Sahaf A, Parvar SY, Ahramiyanpour N · 2023
- 194Rezaei SMA, Mohammadi F, Eftekhari MH, Ejtehadi F, Ghaem H, Mohammadipoor N · 2023
- 195Faghfouri AH, Baradaran B, Khabbazi A, Abdoli Shadbad M, Papi S, Faghfuri E et al. · 2022
- 196Faghfouri AH, Khabbazi A, Baradaran B, Khajebishak Y, Baghbani E, Noorolyai S et al. · 2022
- 197Castro-Marrero J, Zaragozá M, López-Vílchez I, Galmés JL, Domingo JC, Maurel S et al. · 2021
- 198
- 199Karamali M, Heidarzadeh Z, Seifati SM, Samimi M, Tabassi Z, Talaee N et al. · 2016
- 200Heckmann SM, Hujoel P, Habiger S, Friess W, Wichmann M, Heckmann JG et al. · 2005
- 201Fukasawa H, Yamawaki M, Furuya J, Omata K, Kaneko M, Matsuyama T et al. · 2025
- 202Pecoraro L, Zoller T, Atkinson RL, Nisi F, Antoniazzi F, Cavarzere P et al. · 2022
- 203Amooyi L, Alizadeh L, Sarbakhsh P, Shojaei-Zarghani S, Gharekhani A · 2025
- 204Togni L, Sparabombe S, Mascitti M, Barlattani A, Isola G, Lo Russo L et al. · 2026
- 205Gupta V, Rastogi P, Ajay S, Lal N, Verma UP, Singhal R et al. · 2025
- 206Alkaya B, Kayhan HG, Demirbilek F, Sahin M, Totik N, Ozcan M et al. · 2025
- 207Aboushousha A, Kamal Y, Ali S · 2025
- 208de Vargas LDS, Jantsch J, Fontoura JR, Dorneles GP, Peres A, Guedes RP · 2023
- 209
- 210Oliveira RG, Achcar-Feih MC, Nogueira-Pileggi V, Carnevale-Silva A, Carmona F, Aragon DC et al. · 2025
- 211Sivakumar RR, Chinnaiah Govindareddy D, Sahoo J, Bobby Z, Chinnakali P · 2024
- 212Munk DE, Lund Laursen T, Teicher Kirk F, Vilstrup H, Ala A, Gormsen LC et al. · 2022
- 213Keshavarzi A, Hassanalizade A, Ranjbar A, Ghaleiha A, Vafaei SY, Rezaei S et al. · 2021
- 214Heidarzadeh Z, Samimi M, Seifati SM, Ashkezari MD, Ahmadi S, Mahmoodi S et al. · 2017
- 215Veverka DV, Wilson C, Martinez MA, Wenger R, Tamosuinas A · 2009
- 216Liria-Domínguez R, Penny M, Kroon PA, Burgos G, Dainty J, Zeder C et al. · 2023
- 217
- 218Balasubramanian A, Holbrook JT, Canning BJ, Que LG, Castro M, Make BJ et al. · 2023
- 219Sett A, Pradhan S, Sancheti K, Basu D, Datta A, Biswas L et al. · 2019
- 220
- 221Abbasinazari M, Alavian SM, Behnava B, Asgharinia M, Salimi S, Keshvari M et al. · 2014
- 222Barnett JB, Dao MC, Hamer DH, Kandel R, Brandeis G, Wu D et al. · 2016
- 223Leal-Martínez F, Franco D, Peña-Ruiz A, Castro-Silva F, Escudero-Espinosa AA, Rolón-Lacarrier OG et al. · 2020
- 224Parravano M, Tedeschi M, Manca D, Costanzo E, Di Renzo A, Giorno P et al. · 2019
- 225Zavros A, Andreou E, Aphamis G, Bogdanis GC, Sakkas GK, Roupa Z et al. · 2023
- 226Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitisItagaki M, Saruta M, Saijo H, Mitobe J, Arihiro S, Matsuoka M et al. · 2014
- 227Ranisavljev M, Stajer V, Todorovic N, Ostojic J, Cvejic JH, Steinert RE et al. · 2024
- 228Shemais N, Elarab AE, ElNahass H · 2021
- 229Watari I, Oka S, Tanaka S, Aoyama T, Imagawa H, Shishido T et al. · 2013
- 230Berti A, Manera C, Dhelpra I, Tomasin M, Bacci C · 2025
- 231Queille-Roussel C, Odeimi J, Broallier M, Kerob D, Tan J · 2026
- 232Sapp PA, Townsend JR, Kirby TO, Edwards CG, La Monica MB, Ziegenfuss TN et al. · 2026
- 233Sapp PA, Townsend JR, Kirby TO, Edwards CG, La Monica MB, Ziegenfuss TN et al. · 2026
- 234Jäger R, Purpura M, Davis J, Keratsopoulos N, Parra ME, Secrest AH et al. · 2024
- 235Barrie SA, Wright JV, Pizzorno JE, Kutter E, Barron PC · 1987
- 236Pizzo G, Licata ME, La Cara M, Pizzo I, Guiglia R, Melilli D · 2007
- 237Siepmann M, Spank S, Kluge A, Schappach A, Kirch W · 2005
- 238Zhou Y, Zhou Y, Liao B, Chen X, Niu Y, Ren B · 2024
- 239Wessells KR, Adu-Afarwuah S, Arnold CD, Okronipa H, Lartey A, Dewey KG et al. · 2026
- 240Sánchez-Sánchez E, Díaz-Jiménez J, García-García A, Úbeda-Iglesias A, Muñoz-Tejada B, Martínez-Diegues J et al. · 2026
- 241Keenan TDL, Agrón E, Keane PA, Domalpally A, Chew EY, Age-Related Eye Disease Study Research Group et al. · 2025
- 242Asaoka D, Ishihara T, Ezoe S, Hamada I, Kitamura M, Uchino K et al. · 2025
- 243Makiabadi E, Nasrollahzadeh J, Nakhaeizadeh R, Shahparvari MR, Roohelhami E · 2025
- 244Xiao M, Dou T, Ji J, Zhu C, Yuan Y, Zhou H et al. · 2025
- 245Cardinale F, Barattini DF, Centi A, Giuntini G, Bordea MM, Herteg D et al. · 2025
- 246Estorninos E, Lawenko RB, Lebumfacil JD, Posecion JEWC, Delos Reyes VC, Petit-Jean A et al. · 2025
- 247Suárez-Ortegón MF, Ortega-Avila JG, Echeverri I, Mateus JC, Mosquera M · 2025
- 248Cai T, Palumbo F, Miacola C, Ceruti C, Rizzo M, Liguori G et al. · 2024
- 249Abdulah DM, Sulaiman SJ, Ahmed ZW · 2024
- 250Josic U, Maravic T, Mazzitelli C, Rinaldi L, D'Alessandro C, D'Urso D et al. · 2024
- 251Nasrollahzadeh J, Makiabadi E, Reza Shahparvari M, Nilghaz M, Narimani B, Rajabpour Ranjbar Y · 2024
- 252Noce A, Marrone G, Di Lauro M, Vita C, Montalto G, Giorgino G et al. · 2024
- 253Cardinale F, Barattini DF, Martinucci V, Bordea MM, Barattini L, Rosu S · 2024
- 254Jahankhani K, Taghipour N, Nikoonezhad M, Behboudi H, Mehdizadeh M, Kadkhoda D et al. · 2024
- 255Edwards BJ, Adam RL, Gallagher C, Germaine M, Hulton AT, Pullinger SA et al. · 2024
- 256Mastoor-Tehrani S, Samadian F, Esmaily H, Kargar A, Markazi N, Anvari S et al. · 2024
- 257Portillo Siqueiros EY, Santellano-Estrada E, Flores Villalobos MÁ, Roacho Soto MG, Martínez Flórez S · 2024
- 258Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE et al. · 2023
- 259Jenkins T, Aston K, Carrell D, DeVilbiss E, Sjaarda L, Perkins N et al. · 2022
- 260Kiio J, Ochola S, Nduati R, Kuria E, Mathenge S, Okoth J · 2022
- 261García-Guerra A, Rivera JA, Neufeld LM, Quezada-Sánchez AD, Dominguez Islas C, Fernández-Gaxiola AC et al. · 2022
- 262Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trialMazza A, Cicero AF, Ramazzina E, Lenti S, Schiavon L, Casiglia E et al. · 2016
- 263Jiang RS, Twu CW, Liang KL · 2015
- 264Tompkins TA, Renard NE, Kiuchi A · 2007
- 265Nagnur MI, Maryam, Fatima R, Ahsan A, Badgail HA, Malik A · 2026
- 266Sharif R, Thomas P, Zalewski P, Fenech M · 2015
- 267Effect of dietary zinc and phytase supplementation on botulinum toxin treatmentsKoshy JC, Sharabi SE, Feldman EM, Hollier LH, Patrinely JR, Soparkar CN · 2012
- 268Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: a double-blind, placebo-controlled clinical trialEby GA, Halcomb WW · 2006
- 269Sakai F, Yoshida S, Endo S, Tomita H · 2002
- 270Islam MM, Woodhouse LR, Westcott J, Sthity RA, Mim KA, Ahmed M et al. · 2026
- 271Sakae K, Agata T, Kamide R, Yanagisawa H · 2013
- 272
- 273Vermeulen-Serpa KM, Lopes MMGD, Alves CX, Grilo EC, Cunha TA, Miranda CTOF et al. · 2024
- 274Piacenza F, Giacconi R, Costarelli L, Malavolta M · 2023
- 275DiSilvestro RA, Koch E, Rakes L · 2015
- 276Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A · 2001
- 277Sakai F, Yoshida S, Endo S, Tomita H · 1995
- 278Xia W, Li C, Zhao D, Xu L, Kuang M, Yao X et al. · 2022
- 279frontera JA, Rahimian JO, Yaghi S, Liu M, Lewis A, Havenon Ad et al. · 2020
- 280Christian P, Zavala E, Hurley KM, Khatry SK, LeClerq SC, Fune Wu LS et al. · 2025
- 281Fortin S, Razafindratsima Y, Razakandrainy A, Randremanana R, Ralison C, Baldwin D et al. · 2026
- 282Kihagi GW, Mank I, Kurniawan AL, Osei TB, Stieglbauer G, Mbata M et al. · 2026
- 283Khera D, Singh S, Purohit P, Sharma P, Singh K · 2020
- 284McLindon LA, Ried K, Wauchope B, Murnane L, Harradine E, Seman J · 2026
- 285Vogel-González M, Talló-Parra M, Herrera-Fernández V, Pérez-Vilaró G, Chillón M, Nogués X et al. · 2021
- 286Zinc Deficiency Among Children Living with HIV on Antiretroviral therapy in Lagos, NigeriaFakile UO, Akinsete AM, Akintan PE, Oyenusi EE, Abdulraheem KS, Temiye EO · 2025
- 287Unno H, Hasegawa T, Sato M, Kobayashi G, Tone S, Naito Y et al. · 2026
- 288Towersey L, Correia P, Fajgenbaum Feiges M, Euzébio Gonçalves Junior J, Sant'Anna B, Kerob D et al. · 2023
- 289Roeth E, Morris M, Reynolds AP, Reynolds EM, Hungerford R, Livingston EJ et al. · 2025
- 290Verma AK, Tandon S, Graham K, Blom JJ, Russell L, Morgan J et al. · 2026
- 291Smith M, Mitschke S, van der Schoot A · 2026
- 292Sarris J, Byrne GJ, Oliver G, Cribb L, Blair-West S, Castle D et al. · 2022
- 293Kamel A, Abdelseed H, Albalawi Y, Aslsalameen E, Almutairi Y, Alkattan A · 2020
- 294Brocard A, Quereux G, Moyse D, Dreno B · 2010
- 295Belostotsky V, Atkinson SA, Filler G · 2024
- 296Thiel M, Martakis K, Duran I, Dafsari HS, Schiller P, Weliwitage J et al. · 2026
- 297Furumachi K, Hara Y, Hosokawa K, Kurihara A, Kumagai E, Hosohata K et al. · 2026
- 298Bechara N, Tehan P, Gunton JE · 2026
- 299Huang SH, Weng HL, Hung KC, Ho CN, Tsai WW, Lai YC et al. · 2025
- 300Lai YC, Yu TS, Hung KC, Wu JY, Tan PH, Ho CN et al. · 2025
- 301Pritchard J, Struszczak L, Henry C, Lugtmeijer C, Bowtell J, O'Leary M · 2025
- 302Lalosevic J, Gajic-Veljic M, Lalosevic Misovic J, Nikolic M · 2023
- 303Dinardo G, Indolfi C, Klain A, Grella C, Tosca MA, Miraglia Del Giudice M et al. · 2026
- 304Ramgir-Naidu S, Abubakar YA, Soni M · 2026
- 305Phillips ME, Livingstone C, Frampton AE, Hart KH · 2025
- 306Konstantinidis I, Tsokkou S, Gavriilaki E, Delis G, Papamitsou T · 2025
- 307Tekeoğlu İ, Şahin MZ, Kamanlı A, Nas K · 2025
- 308Nakatani S, Morioka T, Morioka F, Mori K, Emoto M · 2025
- 309de Carvalho JF, Martinez ATA · 2025
- 310Nechifor M, Zamfir CL, Gales C · 2025
- 311Sornsil D, Harada KH, Phosri A · 2024
- 312Nin T, Tsuzuki K · 2024
- 313Ahmad R, Shaju R, Atfi A, Razzaque MS · 2024
- 314Berg Y, Gabay E, Božić D, Shibli JA, Ginesin O, Asbi T et al. · 2024
- 315Firouzi S, Pahlavani N, Navashenaq JG, Clayton ZS, Beigmohammadi MT, Malekahmadi M · 2022
- 316
- 317Pedrosa LFC, Barros ANAB, Leite-Lais L · 2022
- 318Scarpellini E, Balsiger LM, Maurizi V, Rinninella E, Gasbarrini A, Giostra N et al. · 2022
- 319Yao DF, Mills JN · 2016
- 320
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.